Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When a medical device manufacturer plans to enter the European market, selecting an EU Authorized Representative (AR) is a foundational compliance step under the Medical Device Regulation (MDR). Beyon...
When a non-EU company developing AI-powered technology, such as a Software as a Medical Device (SaMD), needs to appoint a GDPR Article 27 Representative, what specific criteria beyond basic compliance...
When bringing a moderate-risk (Class II) medical device to market, manufacturers often rely on the 510(k) pathway, demonstrating substantial equivalence to a predicate device. However, for many Class ...
As the medical device industry anticipates significant updates to the ISO 10993-1 standard, expected around 2025/2026, what comprehensive and proactive adjustments should manufacturers make to their b...
For medical device manufacturers, ensuring biocompatibility is a foundational element of a successful regulatory submission. The FDA's framework for the biological evaluation of medical devices has hi...
When preparing for the UK’s evolving medical device regulations, particularly with deadlines approaching in 2026, manufacturers based outside the UK must appoint a UK Responsible Person (UKRP). While ...
For non-EU medical device manufacturers, appointing an Authorised Representative (AR) is a mandatory step for placing products on the European market under the EU Medical Device Regulation (MDR). Howe...
With significant EU cosmetic regulatory updates and compliance deadlines approaching, brands must secure a qualified EU Responsible Person (RP). However, understanding the associated service models is...
For a non-EU company planning its 2026 compliance budget, how can it move beyond a simple price comparison to accurately forecast the total cost of ownership for a GDPR Article 27 Representative, and ...
For a connected medical device, such as a continuous glucose monitoring system or a wireless cardiac monitor, how should a manufacturer structure the cybersecurity documentation within a premarket sub...
For non-EU operators, particularly those in regulated sectors like medical devices who are familiar with appointing an EU Authorized Representative (AR) under the MDR, how should the selection process...
While specific fees for appointing an EU representative for the Carbon Border Adjustment Mechanism (CBAM) vary, what are the primary factors that influence the overall cost and service structure? For ...
With the UK regulatory landscape for medical devices evolving, how should a non-UK based manufacturer conduct a thorough and strategic evaluation to select a UK Responsible Person (UKRP) that ensures ...
With the upcoming UK regulatory deadlines approaching, non-UK based medical device manufacturers must appoint a UK Responsible Person (UKRP) to place devices on the Great Britain market. Simply select...
With the upcoming UK regulatory deadlines approaching, non-UK based medical device manufacturers face the critical task of appointing a UK Responsible Person (UKRP) to maintain market access in Great ...
For non-EU companies placing products on the European market, understanding the evolving role of the EU Responsible Person (RP) is critical, especially with shifting compliance deadlines. What key res...
Given that the EU Medical Device Regulation (MDR) establishes significant shared liability between a non-EU manufacturer and their Authorised Representative (AR), how should a manufacturer structure a...
When evaluating partners to act as an EU Responsible Person (RP) for cosmetic products, what are the key factors and service-level components that determine the overall scope and cost of engagement, e...
For non-EU based companies, particularly those in the medical device and technology sectors, consolidating representative services offers significant operational efficiency. With the General Data Prot...
For companies based outside the European Union, appointing a GDPR Article 27 Representative is a well-established compliance step. However, with the introduction of the EU AI Act, a new layer of compl...